ISPOR, Optum and the Power of Real-World Data

The life sciences industry is facing unprecedented opportunities and challenges, and I’m excited. We’re entering new and diverse markets, unlike any we’ve experienced before, while at the same time the dynamics in existing markets are becoming more complex due to health care transformation efforts.

Why does this excite me? Because there is a tool that addresses these opportunities and challenges. Real-world data.

Real-world data allows us to look at how the world really is, not how we want it to be, to improve the quality of research and speed to market, locally and globally. As an industry, we need to ensure that we are focused on the application of real-world data to our research and development.Brian Kelly

Enter the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) European Congress. Over the past 15 years, the European Congress has brought together global researchers and thought-leaders to advance the latest industry research and scientific knowledge. This year, 2-6 November 2013 in Dublin, the 16th Annual European Congress will play an important role in demonstrating the power of real-world data and how it can help pharmacoeconomics and outcomes research more effectively improve outcomes.

At Optum, we’re harnessing real-world data to positively impact life sciences and the overall health care landscape. Our acquisition of Humedica, and the integration of their clinical data with Optum’s claims data, has created an exciting new asset that I like to call the “Holy Grail” of real-world evidence. This novel class of real-world data is revealing opportunities, risks and outcomes that lead to improved patient outcomes and drive stronger strategic and tactical planning. Working across our organization, we are able to help our clients and partners ask the right questions in order to develop the right research which leads to better results.

This year’s Congress theme, Finding the right pieces of the health care decision making puzzle, is a perfect fit for our industry. By looking at the entire system and understanding the levers that make it work, we can better understand how to use real-world data to put together the right pieces of health economics and outcomes research to improve the quality and affordability of health care and health outcomes. In Dublin, we’ll be exploring topics that range from the opportunity to utilize real-world data to reveal untapped sources of value to evidence-based deterministic sensitivity analyses. To learn more about these topics and to view a full schedule of Optum’s contributions to the ISPOR 16th Annual European Congress click here.

I’m looking forward to attending this year’s Congress and having the opportunity to meet with customers and partners and come together as a global industry to scope out 2014 and beyond. It’s time to put a renewed focus on asking the right questions and leveraging the right data to ensure that we are getting the right answers through research. ISPOR is the perfect venue to help focus us and make sure we are properly using real-world data, our industry currency, to address the changing global economic and regulatory landscape to improve population health.

If you can’t join us in Dublin, I encourage you to get engaged and participate via social media. Follow the ISPOR conference, join the our Twitter discussion at @OptumNews to read more about what we’re doing at the meeting and follow additional discussions at @ISPORorg and #ISPORDublin.

Brian Kelly, President, Optum Life Sciences

Leave a Reply